CCC Diagnostics, Inc Awarded Qualifying Therapeutic Discovery Project Grant
CCC Diagnostics Inc has been awarded a Qualifying Therapeutic
Discovery grant for the DirectHit Test Panel for Breast Cancer. The
funding will allow the company to expand the offerings of the DirectHit test, which is designed to accurately predict the tumor's response to commonly prescribed classes of anti-cancer drugs.
- Baltimore, MD (1888PressRelease) January 20, 2011 - CCC Diagnostics, Inc. has received a grant of $244,479.25 under the Qualifying Therapeutic Discovery Project created by Congress as a component of the Patient Protection and Affordable Care Act of 2010, signed by President Obama on March 23, 2010. This grant was awarded to further development and commercialization of the DirectHitTM Test Panel for Breast Cancer.
DirectHit is a vastly improved diagnostic test for breast cancer treatment that accurately predicts the tumor's response to four commonly prescribed classes of anti-cancer drugs. The DirectHit Test Panel is the only diagnostic test which can predict the responsiveness of breast cancer patients to two classes of chemotherapy drugs, taxanes and capecitabine. In addition, DirectHit is significantly more accurate than existing tests for estrogen receptor and the HER-2/neu.
John Hughes, CEO of CCC Diagnostics, commented " We are very pleased to receive this grant. The funding will allow us to expand the technology of the DirectHit and aid more patients and their physicians in making informed choices about their treatments".
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam